Synlogic (NASDAQ:SYBX) Given “Outperform” Rating at Wedbush

Wedbush reaffirmed their outperform rating on shares of Synlogic (NASDAQ:SYBX) in a research report sent to investors on Friday morning, RTT News reports. The firm currently has a $20.00 target price on the biotechnology company’s stock.

A number of other research firms have also weighed in on SYBX. ValuEngine upgraded shares of Synlogic from a sell rating to a hold rating in a research note on Thursday, August 1st. Zacks Investment Research upgraded shares of Synlogic from a hold rating to a buy rating and set a $9.00 target price on the stock in a research note on Tuesday, July 16th. Piper Jaffray Companies upped their target price on shares of Synlogic from $16.00 to $20.00 and gave the stock an overweight rating in a research note on Monday, July 15th. HC Wainwright upped their target price on shares of Synlogic from $20.00 to $22.00 and gave the stock a buy rating in a research note on Tuesday, July 16th. Finally, Jefferies Financial Group initiated coverage on shares of Synlogic in a research note on Tuesday, April 30th. They set a buy rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The company has an average rating of Buy and a consensus target price of $20.00.

Shares of SYBX stock traded up $0.46 during trading hours on Friday, reaching $5.46. 239,437 shares of the stock were exchanged, compared to its average volume of 249,428. The stock has a fifty day moving average price of $7.49. The company has a debt-to-equity ratio of 0.20, a current ratio of 11.53 and a quick ratio of 11.53. Synlogic has a 12-month low of $4.61 and a 12-month high of $14.59. The stock has a market cap of $120.60 million, a price-to-earnings ratio of -2.69 and a beta of 2.39.

Synlogic (NASDAQ:SYBX) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.04. Synlogic had a negative net margin of 2,005.43% and a negative return on equity of 38.93%. The firm had revenue of $0.35 million for the quarter, compared to analyst estimates of $0.96 million. As a group, research analysts predict that Synlogic will post -1.99 EPS for the current year.

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. increased its stake in Synlogic by 33.4% in the fourth quarter. BlackRock Inc. now owns 1,248,355 shares of the biotechnology company’s stock valued at $8,750,000 after purchasing an additional 312,398 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Synlogic by 50.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 316,656 shares of the biotechnology company’s stock valued at $2,220,000 after purchasing an additional 105,628 shares during the last quarter. Northern Trust Corp increased its stake in Synlogic by 1.2% in the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock valued at $1,172,000 after purchasing an additional 2,005 shares during the last quarter. Geode Capital Management LLC increased its stake in Synlogic by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 155,161 shares of the biotechnology company’s stock valued at $1,087,000 after purchasing an additional 16,591 shares during the last quarter. Finally, Alps Advisors Inc. increased its stake in Synlogic by 4.5% in the first quarter. Alps Advisors Inc. now owns 61,466 shares of the biotechnology company’s stock valued at $467,000 after purchasing an additional 2,658 shares during the last quarter. Institutional investors own 81.89% of the company’s stock.

Synlogic Company Profile

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

See Also: Technical Analysis of Stocks, How Can It Help

Analyst Recommendations for Synlogic (NASDAQ:SYBX)

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.